Evidence map›Paper›PMID 39060738›Full record

ReviewAdvances in experimental medicine and biology2024

Clostridioides difficile Infections: Prevention and Treatment Strategies.

Elvira Ingrid Levy, Meltem Dinleyici, Ener Dinleyici, Yvan Vandenplas

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Elvira Ingrid LevyDepartment of Pediatrics, C.H.U. Saint-Pieter, Free University of Brussels, Brussels, Belgium.
Meltem DinleyiciEskisehir Osmangazi University Faculty of Medicine, Department of Social Pediatrics, Eskisehir, Turkey.
Ener DinleyiciDepartment of Pediatrics, Eskisehir Osmangazi University School of Medicine, Eskisehir, Turkey.
Yvan VandenplasVrije Universiteit Brussel (VUB), UZ Brussel, KidZ Health Castle, Brussels, Belgium. Yvan.vandenplas@uzbrussel.be.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clostridioides difficile is the most common causative agent of antibiotic-associated diarrhea. This spore forming, obligate anaerobic, gram-positive bacillus is becoming responsible for an increasing number of infections worldwide, both in community and in hospital settings, whose severity can vary widely from an asymptomatic infection to a lethal disease. While discontinuation of antimicrobial agents and antibiotic treatment of the infection remain the cornerstone of therapy, more recent fecal microbiota transplantation has also been valid as a therapy. The use of probiotics, especially Saccharomyces boulardii CNCM I-745 have become valid forms of prevention therapy. Although there are studies in adults with microbiota-targeted new generation therapies and Clostridium difficile vaccines, there are no data in the paediatric age group yet.

Indexed as

Anti-Bacterial AgentsClostridioides difficileClostridium InfectionsFecal Microbiota TransplantationProbioticsDiarrheaGastrointestinal MicrobiomeHumansAnti-Bacterial AgentsChildrenClostridioides (Clostridium) difficilePreventionProbioticsRecurrenceTreatmentYeast

Identifiers

PMID39060738

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.